An experimental drug under development byTetra Discovery Partners LLChas the potential to treat traumatic brain injury, according to the results of a pre-clinical trial.
In testing on rats, researchers at theUniversity of Miami’sTraumatic Brain InjuryInstitute found that the Grand Rapids-based Tetra’s compound, known as PDE4, reduced chronic cognitive deficits after traumatic brain injury.
The results “suggest that PDE4B inhibition has the potential to improve learning and memory ability and overall functioning for people living with TBI (traumatic brain injury),” according to a statement today from the University of Miami and Tetra Discovery Partners.